RxDoctor Payments Data

Zaid Haddad, MD

Nephrology · Chicago, ILNPI 1538509971

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 30 payments — averaging $38.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$260
  • AstraZeneca$224
  • Otsuka America Pharmaceutical, Inc.$119
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$109
  • Boehringer Ingelheim$108
  • Fresenius USA Marketing, Inc.$108
  • plus $239 from 6 others

What the payments were for

  • Food & beverage$92579%
  • Education$24121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,166 in reported general payments places this provider in the 55th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$160,345
Medicare patients
216
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$42,546
AuryxiaFerric Citrate31$35,842
VelphoroSucroferric Oxyhydroxide13$34,145
LokelmaSodium Zirconium Cyclosilicate25$18,243
FarxigaDapagliflozin Propanediol16$10,606
Sevelamer Carbonate84$7,916
Sevelamer Hcl12$6,290
Calcitriol44$1,179
Bumetanide33$977
Nifedipine ErNifedipine35$834
Losartan Potassium90$387
Hydralazine Hcl19$276
Amlodipine Besylate31$186
Furosemide39$135
Carvedilol24$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$108$42,54661 claims
Fresenius USA Marketing, Inc.Velphoro$108$34,14513 claims
AstraZenecaLokelma, Farxiga$224$28,84941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 524 nephrology providers in Illinois.

Other nephrology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →